Type 2 Diabetes Clinical Trial
Official title:
h-Patch vs. Pen or Needle and Syringe as Insulin Administration Device in Type 1 or 2 Diabetes Patients Using MDI: Patient Preference and Glycemic Control After Switch in an Open-Label, Randomized Cross-Over Study
Verified date | March 2007 |
Source | Valeritas, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The primary objective of this study is to compare patient preference of the h-Patch as delivery device for insulin lispro compared with either an insulin pen or needle and syringe in patients with diabetes, either Type 1 or Type 2, on stable multiple daily injection regimens. This will be assessed using an accepted preference scale.
Status | Terminated |
Enrollment | 11 |
Est. completion date | September 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Diagnosis of Type 1or Type 2 diabetes mellitus for at least a year 2. Stable insulin regimen for at least 3 months consisting of multiple daily injections of human regular or rapid acting insulin at meal times and long or intermediate acting insulin as basal. In this protocol multiple daily injections requires at least three injections daily. 3. Total daily insulin dose between 50 and 80 units. 4. If patient is Type 2, can be treated with metformin and/or a thiazolidinedione and/or a sulfonylurea, but other diabetes drugs including a-glucosidase inhibitors, meglitinides, pramlintide exenatide, and DPP-IV's are excluded. 5. HbA1c > 7.0% and < 9.0%. Exclusion Criteria: 1. Recurrent major hypoglycemia or prolonged unstable blood glucose control (as judged by the Investigator). 2. Use of other diabetes drugs including a-glucosidase inhibitors, meglitinides, pramlintide, exenatide or DPP-IV inhibitors (metformin and/or a thiazolidinedione and/or a sulfonylurea are allowed). 3. Intend to use any other concomitant drug therapy (prescription or over-the-counter medications) that can affect blood glucose levels. 4. Have used systemic glucocorticoids within 1 month prior to Screening or currently on glucocorticoids. 5. Have a history of drug or alcohol abuse within 1 year prior to Screening Visit. 6. Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, or neurological disease that would, in the investigator's opinion, preclude safe participation in the study. 7. Have a history of major surgery, e.g. laparotomy, thoracotomy, open orthopedic procedure, etc. within 3 months prior to Screening Visit. 8. Evidence of significant neuropsychiatric disease. 9. Have participated in a medical, surgical, or pharmaceutical investigational new drug/device study in the last 30 days or = 5 half-lives of the investigational drug, whichever is longer, prior to Screening Visit. 10. Blood donation of 500 ml or more in the last 2 months prior to Screening Visit. 11. Evidence of significant active hematological disease. 12. Acute infection with fever. 13. Hemoglobin < 10 g/dL; AST, ALT = 1.5 times the upper reference limit at Screening. 14. Uncontrolled treated/untreated hypertension (systolic blood pressure > 155 mmHg and diastolic blood pressure > 90 mmHg). 15. History of proliferative retinopathy or maculopathy requiring acute treatment 16. Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation. 17. Any condition that the Investigator and/or Sponsor feel would interfere with trial participation or evaluation of results 18. Pregnancy, breast-feeding, intention of becoming pregnant for female patients of child-bearing potential. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Diabetes and Glandular Research | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Valeritas, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Secondary | Mean glucose using CGM. | 4 weeks | ||
Secondary | Glucose SD, MAGE, Proportion of 24 hours in euglycemic range 70-160 mg/dl, using CGM. | 4 weeks | ||
Secondary | End of Study Patient Questions | 4 weeks | ||
Secondary | Hypoglycemia | 4 weeks | ||
Secondary | Proportion of time with glucose < 70 mg/dl, from CGM. | 4 weeks | ||
Secondary | Number and type of adverse events. | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |